Benzinga | Dec 8, 2021 08:37AM EST

Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $129

Citigroup analyst Neena Bitritto-Garg maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $127 to $129.